Nasdaq
$147.61▲ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.92BShares out 40.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 6d agoPre-market26.10.19 19:016-KKey event#●●●#●●●
BELITE BIO, INCBullish
Belite Bio has transferred its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market commenced on October 19, 2026, under the existing ticker symbol 'BLTE'.…more
$147.61+0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 08:274Ownership
BELITE BIO, INC
Insider Hendrik Peter Scholl of Belite Bio, Inc. filed a Form 4 statement of changes in beneficial ownership of securities, effective October 1, 2026. This filing officially records the changes in the insider's equity holdings.…more
$147.61+0.03%vs prev closeView filingShare - 10.1After-hours26.10.02 07:04144Ownership
BELITE BIO, INC
Hendrik Peter Scholl, an insider of Belite Bio, Inc., has filed Form 144 to report the proposed sale of company securities. This filing serves as a standard notification regarding the insider's plan to dispose of their holdings.…more
$147.61+0.03%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 19:00#●●●
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Belite Bio has successfully transferred its listing to the Nasdaq Global Select Market, the exchange's highest tier. This transition is expected to enhance the company's visibility among institutional investors and improve market liquidity.…more
$147.61+0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14After-hours26.10.15 05:00
●●●●●●●● ●●●●● ●●●●●●
Belite Bio has submitted marketing authorization applications for its Stargardt disease treatment, tinlarebant, in Singapore, the United Kingdom, and Switzerland. While the company is also pursuing approvals in the U.S. and Japan, the final commercial viability remains subject to regulatory review.…more
$147.61+0.03%vs prev close - 9.29Overnight26.09.29 09:00
●●●●●●●● ●●●●● ●●●●●●
Belite Bio announced it will present Phase 3 clinical trial results for its Stargardt disease treatment candidate at the upcoming Euretina medical conferences in Austria. This presentation serves as an academic update while the company's drug application remains under FDA priority review.…more
$147.61+0.03%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report